Petros director granted 4.38M restricted shares

Silverman Joshua reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Silverman Joshua reported acquisition or exercise transactions in this Form 4 filing.

Petros Pharmaceuticals director Joshua Silverman reported receiving a large stock award in the form of restricted common shares. He was granted 4,375,000 shares of Petros Pharmaceuticals common stock as a grant or award, rather than an open-market purchase.

According to the terms, 50% of these restricted shares vested on the grant date, while the remaining 50% will vest six months after the grant date if he is still providing services to the company at that time. Following this grant, Silverman directly holds a total of 8,790,450 shares of Petros Pharmaceuticals common stock.

Insider Trade Summary

Grant/Award: 4,375,000 shares

Grant/Award 1 txn

Insider Silverman Joshua

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	4,375,000	$0.00	$0.00

Holdings After Transaction: Common Stock — 8,790,450 shares (Direct)

Footnotes (1)

1. F1. Represents restricted shares ("Shares") of common stock, par value $0.0001 per share, of the Issuer. 50% of the Shares vested on the date of grant and the remaining 50% will vest on the six-month anniversary of the date of grant, provided that the Reporting Person is providing services to the Issuer on such vesting date.

Key Figures

Restricted shares granted: 4,375,000 shares Immediate vesting portion: 50% of 4,375,000 shares Deferred vesting portion: 50% of 4,375,000 shares +2 more

5 metrics

Restricted shares granted 4,375,000 shares Common stock grant/award on grant date

Immediate vesting portion 50% of 4,375,000 shares Vested on grant date

Deferred vesting portion 50% of 4,375,000 shares Vest six months after grant if still providing services

Shares held after transaction 8,790,450 shares Total direct common stock holdings following grant

Transaction price per share $0.0000 per share Reported for the restricted stock grant

Key Terms

restricted shares, vested, grant, award, or other acquisition, par value

4 terms

restricted shares financial

"Represents restricted shares ("Shares") of common stock, par value $0.0001 per share, of the Issuer."

Restricted shares are company stock that cannot be sold or transferred immediately because they are subject to legal or contractual limits, such as a required holding period or performance conditions. They matter to investors because these locked-up shares can affect a company’s available stock for trading, future dilution, and insider incentives—imagine a gift that can’t be cashed until certain conditions are met, which changes when and how much supply can suddenly enter the market.

vested financial

"50% of the Shares vested on the date of grant and the remaining 50% will vest on the six-month anniversary of the date of grant"

grant, award, or other acquisition financial

"transaction_code_description: "Grant, award, or other acquisition""

par value financial

"common stock, par value $0.0001 per share, of the Issuer."

Par value is the fixed amount printed on a bond or stock that represents its original value when issued. It’s like the face value of a coin or bill—what the issuer promises to pay back or the starting price of a stock—though it often doesn’t change with market prices. It matters because it helps determine certain financial details, like how much the company will pay back at maturity.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Petros Pharmaceuticals (PTPI) director Joshua Silverman report on this Form 4?

Joshua Silverman reported an acquisition of Petros Pharmaceuticals common stock through a stock award. He received 4,375,000 restricted shares, with vesting tied to his continued service, increasing his direct holdings to 8,790,450 shares after the grant.

How many Petros Pharmaceuticals (PTPI) shares were granted to Joshua Silverman?

Joshua Silverman was granted 4,375,000 restricted shares of Petros Pharmaceuticals common stock. These were reported as a grant, award, or other acquisition, rather than an open‑market transaction, and carry specific vesting conditions based on his continued service to the company.

What is the vesting schedule for Joshua Silverman’s PTPI restricted shares?

Half of the 4,375,000 restricted shares vested on the grant date, and the remaining half will vest six months after the grant date. The second tranche will only vest if Joshua Silverman is still providing services to Petros Pharmaceuticals on that future vesting date.

What are Joshua Silverman’s total PTPI holdings after this stock award?

After receiving the 4,375,000 restricted shares, Joshua Silverman directly holds 8,790,450 shares of Petros Pharmaceuticals common stock. This figure reflects his position immediately following the reported grant, as disclosed in the Form 4 filing’s post‑transaction holdings data.

Was cash paid for Joshua Silverman’s newly acquired PTPI shares?

The reported transaction price per share was $0.0000, indicating the shares were received as a stock award rather than bought in the market. The filing classifies the transaction as a grant, award, or other acquisition of common stock, not an open‑market purchase.

Are Joshua Silverman’s new PTPI shares fully vested today?

Only 50% of the 4,375,000 restricted shares vested immediately on the grant date. The remaining 50% is scheduled to vest six months after the grant date, contingent on Joshua Silverman continuing to provide services to Petros Pharmaceuticals at that vesting time.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/05/2026 - 05:12 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Silverman Joshua

(Last) (First) (Middle)

C/O PETROS PHARMACEUTICALS, INC.

1185 AVENUE OF THE AMERICAS, 3RD FLOOR

(Street)

NEW YORK NEW YORK 10036

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Petros Pharmaceuticals, Inc. [ PTPI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/05/2026		A		4,375,000(1)	A	$0(1)	8,790,450	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents restricted shares ("Shares") of common stock, par value $0.0001 per share, of the Issuer. 50% of the Shares vested on the date of grant and the remaining 50% will vest on the six-month anniversary of the date of grant, provided that the Reporting Person is providing services to the Issuer on such vesting date.

	/s/ Joshua Silverman	06/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)